BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Spero Therapeutics (SPRO)Spero TherapeuticsConference / presentation

In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents

Study highlighting SPR720 potential benefits for prolonged combination regimens typical to NTM-PD treatment

CAMBRIDGE,...

Related news

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IMNNImunon2026-07-23 13:25 EST

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

AVIRAtea2026-01-08 12:00 EST

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

AVIRAtea2026-01-06 12:00 EST

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

MBRXMoleculin Biotech, Inc.2026-05-21 21:02 EST

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

COCPCocrystal Pharma2026-04-30 20:05 EST

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

COCPCocrystal Pharma2026-02-19 13:00 EST

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

ANTXAN2 Therapeutics2026-02-17 12:00 EST

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Stock data

Close
1.22 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States